阿司匹林心血管疾病一级预防最新研究的解读与启示  

Interpretation of three latest trials of aspirin in primary prevention of cardiovascular diseases

作　　者：施仲伟[1] 谢良地[2] 孔祥清[3] 许之民[4] 罗和生[5] 宋现涛[6] 卢永昕[7] 张梅[8] 张慧敏[9] 陆志刚[10] Shi Zhongwei;Xie Liangdi;Kong Xiangqing;Xu Zhimin;Luo Hesheng;Song Xiantao;Lu Yongxin;Zhang Mei;Zhang Huimin;Lu Zhigang(Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;Department of Cardiology, Shanghai Jiao Tong University Affiliated 6th People′s Hospital, Shanghai 200233, China;Department of Geriatrics, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China;Department of Cardiology, Jiangsu Province Hospital, Nanjing210029, China;Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200029, China;Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China;Department of Cardiology Ward 1, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China;Department of Cardiology, Qilu Hospital of Shandong University, Ji′nan 250012, China;Hypertension Center, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China)

机构地区：[1]上海交通大学医学院附属瑞金医院心内科,200025 [10]上海交通大学附属第六人民医院心内科,200233 [2]福建医科大学附属第一医院干部保健科,福州350005 [3]江苏省人民医院心内科,南京210029 [4]上海交通大学医学院附属新华医院心内科200029 [5]武汉大学人民医院消化内科,430060 [6]首都医科大学附属北京安贞医院心内一科A区,100029 [7]华中科技大学同济医学院附属协和医院心血管内科,武汉430022 [8]山东大学齐鲁医院心血管内科,济南250012 [9]中国医学科学院北京协和医学院阜外医院高血压中心,100037

出　　处：《中华内科杂志》2019年第4期252-257,共6页Chinese Journal of Internal Medicine

摘　　要：阿司匹林的心血管疾病(CVD)一级预防作用存在争议,既往临床试验及汇总分析提示其获益大于风险。然而随着人群CVD预防整体水平的不断提高,阿司匹林的获益-风险比趋于缩小,最近发表的阿司匹林一级预防研究结果再次引发各界热烈讨论。本文通过复习相关文献、解读这三项研究,以及对比我国和美国的CVD流行趋势及预防现状,认为阿司匹林仍可用于我国人群CVD一级预防,并就如何适当应用阿司匹林提出了若干建议。

关 键 词：阿司匹林 动脉粥样硬化性心血管疾病 一级预防 

分 类 号：R54[医药卫生—心血管疾病]